Acute activation, desensitization and smoldering activation of human acetylcholine receptors

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Campling, Barbara G ^a,b   Kuryatov, Alexander ^a   Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; NICOTINE; NICOTINIC AGENT;

CELL LINE; DOSE RESPONSE; GENETICS; HUMAN; METABOLISM;

CELL LINE; CHOLINERGIC AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, CHOLINERGIC;

EID: 84893705363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079653     Document Type: Article

References (57)

1. Millar NS, Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. [Review] [162 refs]. Neuropharmacol 56: 237-246.
2. Lindstrom JM (2002) Acetylcholine receptor structure. In: Kaminski HJ, editors. Current Clinical Neurology: Mysathenia Gravis and Related Disorders. Towata, NJ: Humana Press Inc. 15-52.
3. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, et al. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78: 703-711.
4. Harpsøe K, Ahring PK, Christensen JK, Jensen ML, Peters D, et al. (2011) Unraveling the high-and low-sensitivity agonist responses of nicotinic acetylcholine receptors. The Journal of Neuroscience 31: 10759-10766.
5. 2α4 nicotinic receptor influences agonist sensitivity. J Biol Chem 286: 31043-31054.
6. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, et al. (2008) Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. The Journal of Neuroscience 28: 12318-12327.
7. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011) Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471: 597-601.
8. Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, et al. (1999) Megacystis, mydriasis, and ion channel defect in mice lacking the α3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 96: 5746-5751. (Pubitemid 29234689)
9. Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, et al. (2007) Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 74: 1102-1111. (Pubitemid 47432651)
10. Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: From basic science to therapeutics. Pharmacology & Therapeutics 137: 22-54.
11. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, et al. (2005) Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477. (Pubitemid 40664098)
12. Levin ED, Rezvani AH, Xiao Y, Slade S, Cauley M, et al. (2010) Sazetidine-A, a selective α4β2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther 332: 933-939.
13. Lee C-H, Zhu C, Malysz J, Campbell T, Shaunessy T, et al. (2011) α4β2 neuronal nicotinic receptor positive allosteric modulation: An approach for improving the therapeutic index of α4β2 nAChR agonists in pain. Biochem Pharmacol 82: 959-966.
14. AlSharari SD, Carroll FI, McIntosh JM, Damaj MI (2012) The antinociceptive effects of nicotinic partial agonists varenicline and sazetidine-A in murine acute and tonic pain models. J Pharmacol Exp Ther 342: 742-749.
15. Turner JR, Castellano LM, Blendy JA (2010) Nicotinic partial agonists for anxiety and depression. Journal of Pharmacology and Experimental Therapeutics 334: 665-672.
16. Caldarone BJ, Wang D, Paterson NE, Manzano M, Fedolak A, et al. (2011) Dissociation between the duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380. Psychopharmacology 217: 199-210.
17. Rezvani A, Slade S, Wells C, Petro A, Lumeng L, et al. (2010) Effects of sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology 211: 161-174.
18. Hussmann GP, Turner JR, Lomazzo E, Venkatesh R, Cousins V, et al. (2012) Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther 343: 441-450.
19. Hussmann GP, Kellar KJ (2012) A new radioligand binding assay to measure the concentration of drugs in rodent brain ex vivo. J Pharmacol Exp Ther 343: 434-440.
20. Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2008) It is not "either/or": Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Progress in Neurobiology 84: 329-342.
21. Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, et al. (1998) Chronic nicotine treatment up-regulates human α3β2, but not α3β4 acetylcholine receptors stably transfected in human embryonic kidney cells. 273 28721: 28732.
22. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J (2003) Alternate stoichiometries of human α4β2 nicotinic acetylcholine receptors. Mol Pharmacol 63: 332-341. (Pubitemid 36158368)
23. Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to upregulate human α4β2 AChRs. Mol Pharmacol 68: 1839-1.
24. Tumkosit P, Kuryatov A, Luo J, Lindstrom J (2006) β3 subunits promote expression and nicotine-induced up-regulation of human nicotinic α6* nicotinic acetylcholine receptors expressed in transfected cell lines. Mol Pharmacol 70: 1358-1368. (Pubitemid 44435988)
25. Kuryatov A, Mukherjee J, Lindstrom J (2013) Chemical chaperones exceed the chaperone effect of RIC-3 in promoting assembly of functional α7 AChRs. PLoS ONE 8 (4): e62246.
26. + efflux with high and low sensitivity to stimulation by acetylcholine. Neuropharmacol 53: 390-405.
27. + efflux in cortex and thalamus and alters relative expression of α4 and β2 subunits. Molecular Pharmacology 73: 1796-1807.
28. 3 human acetylcholine receptors. Mol Pharmacol 71: 769-776.
29. Moroni M, Zwart R, Sher E, Cassels BK, Bermudez I (2006) α4β2 nicotinic receptors with high and low acetylcholine sensitivity: Pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70: 755-768. (Pubitemid 44092336)
30. 2 nicotinic acetylcholine receptors: subunit arrangement determines functional expression. Br J Pharm 156: 970-981.
31. 2+ permeability, conductance, and gating of human α4β2 nicotinic acetylcholine receptors. J Neurosci 17: 9035-9047.
32. Peng X, Katz M, Gerzanich V, Anand R, Lindstrom J (1993) Human α7 acetylcholine receptor: Cloning of the α7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of mature receptors and functional α7 homomers expressed in Xenopus oocytes. Mol Pharmacol 45: 546-554.
33. Margolskee RF, McHendry-Rinde B, Horn R (1993) Panning transfected cells for electrophysiological studies. Biotechniques 15: 906-911. (Pubitemid 23333288)
34. Nelson ME, Wang F, Kuryatov A, Choi CH, Gerzanich V, et al. (2001) Functional properties of human nicotinic AChRs expressed by IMR-32 neuroblastoma cells resemble those of α3β4 AChRs expressed in permanently transfected HEK cells. J Gen Physiol 118: 563-582. (Pubitemid 33064292)
35. Conroy WG, Liu QS, Nai Q, Margiotta JF, Berg DK (2003) Potentiation of α7-containing nicotinic acetylcholine receptors by select albumins. Mol Pharmacol 63: 419-428. (Pubitemid 36158378)
36. Papke RL, Papke JKP (2002) Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis. Br J Pharm 137: 49-61. (Pubitemid 34983463)
37. Olale F, Gerzanich V, Kuryatov A, Wang F, Lindstrom J (1997) Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther 283: 675-683. (Pubitemid 27514626)
38. Magnus CJ, Lee PH, Atasoy D, Su HH, Looger LL, et al. (2011) Chemical and genetic engineering of selective ion channel-ligand interactions. Science 333: 1292-1296.
39. Papke RL, Trocmé-Thibierge C, Guendisch D, Al Rubaiy SAA, Bloom SA (2011) Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J Pharmacol Exp Ther 337: 367-379.
40. Papke R (2010) Tricks of Perspective: Insights and limitations to the study of macroscopic currents for the analysis of nAChR activation and desensitization. Journal of Molecular Neuroscience 40: 77-86.
41. Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, et al. (2007) In vitro screening strategies for nicotinic receptor ligands. Biochem Pharmacol 74: 1172-1181. (Pubitemid 47417928)
42. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, et al. (2006) Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34: 121-130. (Pubitemid 43042653)
43. Benowitz NL, Kuyt F, Jacob P (1982) Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 32: 758-764. (Pubitemid 13093847)
44. Xiao Y, Fan H, Musachio JL, Wei Z-L, Chellappan SK, et al. (2006) Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 70: 1454-1460. (Pubitemid 44435998)
45. Jia L, Flotildes K, Li M, Cohen BN (2003) Nicotine trapping causes the persistent desensitization of α4β2 nicotinic receptors expressed in oocytes. J Neurochem 84: 753-766.
46. Etter J-F (2006) Cytisine for smoking cessation. A literature review and a meta-analysis. Arch Intern Med 166: 1553-1559.
47. Papke RL, Heinemann SF (1994) Partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit. Mol Pharmacol 45: 142-149. (Pubitemid 24042293)
48. Cahill K, Stead LF (2011) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2: 1-87.
49. Kozikowski AP, Eaton JB, Bajjuri KM, Chellappan SK, Chen Y, et al. (2009) Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2- ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. ChemMedChem 4: 1279-1291.
50. Cucchiaro G, Xiao Y, Gonzalez-Sulser A, Kellar KJ (2008) Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology 109: 512-519.
51. Zwart R, Carbone A, Moroni M, Bermudez I, Mogg AJ, et al. (2008) Sazetidine-A is a potent and selective agonist at native and recombinant α4β2 nicotinic acetylcholine receptors. Mol Pharmacol 73: 1838-1843. (Pubitemid 351724371)
52. Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, et al. (2006) Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63: 907-915. (Pubitemid 44192334)
53. Luetje CW, Patrick J (1991) Both α- and β-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. Neuroscience 11: 837-845.
54. Astroug H, Simeonova R, Kassabova LV, Danchev N, Svinarov D (2010) Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits. Interdisc Toxicol 3: 15-20.
55. Faessel HM, Obach RS, Rollema H, Ravva R, Williams KE, et al. (2010) A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokin 49: 799-816.
56. 3 receptor. JPET 339: 125-131.
57. Liu Y, Richardson J, Tran T, Al-Muhtasib N, Xie T, et al. (2013) Chemistry and pharmacological studies of 3-Alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. J Med Chem 56: 3000-3011.